Business Context and Reporting Period
Company: Skye Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 27, 2021
Event: Entry into a Material Definitive Agreement for a registered direct offering.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than operational financial results. Key transaction metrics include:
- Gross Proceeds: Approximately $7.0 million (before fees and expenses).
- Securities Issued:
- 58,111,112 shares of common stock.
- Pre-funded warrants to purchase up to 19,666,667 shares.
- Series A Warrants to purchase up to 77,777,779 shares.
- Purchase Price: $0.09 per Share and Series A Warrant; $0.0899 per Pre-Funded Warrant.
- Warrant Terms: Series A Warrants exercisable for 5 years at $0.09/share. Pre-Funded Warrants exercisable immediately at $0.0001/share.
- Placement Agent Fees: 7.5% cash fee on gross proceeds, 1.0% management fee, $75,000 non-accountable expenses, $15,950 clearing expenses, plus warrants to purchase 5,444,445 shares (7.0% of aggregate shares sold).
Material Changes and Agreements
The primary material change is the execution of a Securities Purchase Agreement with institutional investors. Additional agreements include:
- Lock-up Agreements: Directors and executive officers agreed not to sell equity securities for 90 days following the closing.
- Ownership Blockers: Holders are restricted from exercising warrants if it results in ownership exceeding 4.99% (or 9.99% with 61 days' prior notice).
- Closing Date: Expected on or about September 29, 2021.
Guidance, Outlook, and Risks
Management Commentary: The filing does not contain forward-looking guidance, revenue projections, or management commentary on operational outlook. The transaction is intended to raise capital for the Company.
Risks and Contingencies:
- Closing is subject to satisfaction of customary conditions.
- Dilution to existing shareholders due to the issuance of shares and warrants.
- Significant fees paid to the placement agent reduce net proceeds.
Unusual Items: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are not reported in this specific 8-K filing.
Investor Verification Checklist
- Verify the actual closing date and final gross proceeds received.
- Confirm the total number of shares outstanding post-offering to assess dilution impact.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and adjustment mechanisms.
- Check subsequent filings for the use of proceeds and updated cash position.
- Monitor compliance with the 90-day lock-up period for insiders.